* Intercardia Inc., of Research Triangle Park, N.C., and Interneuron Pharmaceuticals Inc., of Lexington, Mass., said the merger between Intercardia and Transcell Technologies Inc., of Monmouth Junction, N.J., is complete, along with Intercardia's acquisition of Interneuron technology in exchange for Intercardia common stock valued at about $14.2 million. Intercardia and Transcell are subsidiaries of Interneuron. (See BioWorld Today, Nov. 7, 1997, p. 1.)

No Comments